BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35013316)

  • 21. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
    Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
    Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preferred nucleotide contexts of the AID/APOBEC cytidine deaminases have differential effects when mutating retrotransposon and virus sequences compared to host genes.
    Chen J; MacCarthy T
    PLoS Comput Biol; 2017 Mar; 13(3):e1005471. PubMed ID: 28362825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
    Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
    Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
    Zhang L; Zhou Y; Cheng C; Cui H; Cheng L; Kong P; Wang J; Li Y; Chen W; Song B; Wang F; Jia Z; Li L; Li Y; Yang B; Liu J; Shi R; Bi Y; Zhang Y; Wang J; Zhao Z; Hu X; Yang J; Li H; Gao Z; Chen G; Huang X; Yang X; Wan S; Chen C; Li B; Tan Y; Chen L; He M; Xie S; Li X; Zhuang X; Wang M; Xia Z; Luo L; Ma J; Dong B; Zhao J; Song Y; Ou Y; Li E; Xu L; Wang J; Xi Y; Li G; Xu E; Liang J; Yang X; Guo J; Chen X; Zhang Y; Li Q; Liu L; Li Y; Zhang X; Yang H; Lin D; Cheng X; Guo Y; Wang J; Zhan Q; Cui Y
    Am J Hum Genet; 2015 Apr; 96(4):597-611. PubMed ID: 25839328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer.
    Trevino V
    Mol Genet Genomic Med; 2019 Aug; 7(8):e810. PubMed ID: 31294536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
    Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
    BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.
    Kumar S; Clarke D; Gerstein MB
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):18962-18970. PubMed ID: 31462496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational processes contributing to the development of multiple myeloma.
    Hoang PH; Cornish AJ; Dobbins SE; Kaiser M; Houlston RS
    Blood Cancer J; 2019 Aug; 9(8):60. PubMed ID: 31387987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CNCDatabase: a database of non-coding cancer drivers.
    Liu EM; Martinez-Fundichely A; Bollapragada R; Spiewack M; Khurana E
    Nucleic Acids Res; 2021 Jan; 49(D1):D1094-D1101. PubMed ID: 33095860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signatures of mutational processes in human cancer.
    Alexandrov LB; Nik-Zainal S; Wedge DC; Aparicio SA; Behjati S; Biankin AV; Bignell GR; Bolli N; Borg A; Børresen-Dale AL; Boyault S; Burkhardt B; Butler AP; Caldas C; Davies HR; Desmedt C; Eils R; Eyfjörd JE; Foekens JA; Greaves M; Hosoda F; Hutter B; Ilicic T; Imbeaud S; Imielinski M; Jäger N; Jones DT; Jones D; Knappskog S; Kool M; Lakhani SR; López-Otín C; Martin S; Munshi NC; Nakamura H; Northcott PA; Pajic M; Papaemmanuil E; Paradiso A; Pearson JV; Puente XS; Raine K; Ramakrishna M; Richardson AL; Richter J; Rosenstiel P; Schlesner M; Schumacher TN; Span PN; Teague JW; Totoki Y; Tutt AN; Valdés-Mas R; van Buuren MM; van 't Veer L; Vincent-Salomon A; Waddell N; Yates LR; ; ; ; ; Zucman-Rossi J; Futreal PA; McDermott U; Lichter P; Meyerson M; Grimmond SM; Siebert R; Campo E; Shibata T; Pfister SM; Campbell PJ; Stratton MR
    Nature; 2013 Aug; 500(7463):415-21. PubMed ID: 23945592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic hypermutation in immunity and cancer: Critical analysis of strand-biased and codon-context mutation signatures.
    Steele EJ
    DNA Repair (Amst); 2016 Sep; 45():1-24. PubMed ID: 27449479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
    Narayan S; Bader GD; Reimand J
    Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide mapping of somatic mutation rates uncovers drivers of cancer.
    Sherman MA; Yaari AU; Priebe O; Dietlein F; Loh PR; Berger B
    Nat Biotechnol; 2022 Nov; 40(11):1634-1643. PubMed ID: 35726091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns and processes of somatic mutations in nine major cancers.
    Jia P; Pao W; Zhao Z
    BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
    Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
    McGranahan N; Favero F; de Bruin EC; Birkbak NJ; Szallasi Z; Swanton C
    Sci Transl Med; 2015 Apr; 7(283):283ra54. PubMed ID: 25877892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
    Vural S; Simon R; Krushkal J
    Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hotspot propensity across mutational processes.
    Arnedo-Pac C; Muiños F; Gonzalez-Perez A; Lopez-Bigas N
    Mol Syst Biol; 2024 Jan; 20(1):6-27. PubMed ID: 38177930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    Nik-Zainal S; Davies H; Staaf J; Ramakrishna M; Glodzik D; Zou X; Martincorena I; Alexandrov LB; Martin S; Wedge DC; Van Loo P; Ju YS; Smid M; Brinkman AB; Morganella S; Aure MR; Lingjærde OC; Langerød A; Ringnér M; Ahn SM; Boyault S; Brock JE; Broeks A; Butler A; Desmedt C; Dirix L; Dronov S; Fatima A; Foekens JA; Gerstung M; Hooijer GK; Jang SJ; Jones DR; Kim HY; King TA; Krishnamurthy S; Lee HJ; Lee JY; Li Y; McLaren S; Menzies A; Mustonen V; O'Meara S; Pauporté I; Pivot X; Purdie CA; Raine K; Ramakrishnan K; Rodríguez-González FG; Romieu G; Sieuwerts AM; Simpson PT; Shepherd R; Stebbings L; Stefansson OA; Teague J; Tommasi S; Treilleux I; Van den Eynden GG; Vermeulen P; Vincent-Salomon A; Yates L; Caldas C; van't Veer L; Tutt A; Knappskog S; Tan BK; Jonkers J; Borg Å; Ueno NT; Sotiriou C; Viari A; Futreal PA; Campbell PJ; Span PN; Van Laere S; Lakhani SR; Eyfjord JE; Thompson AM; Birney E; Stunnenberg HG; van de Vijver MJ; Martens JW; Børresen-Dale AL; Richardson AL; Kong G; Thomas G; Stratton MR
    Nature; 2016 Jun; 534(7605):47-54. PubMed ID: 27135926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.